COMMUNIQUÉS West-GlobeNewswire

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

23/06/2017 - 10:40

CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2- advanced breast cancer[ [...]

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®

23/06/2017 - 08:40

New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna [...]

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

23/06/2017 - 08:35

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63 patients demonstrate relapse- [...]

Virbac :Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017

23/06/2017 - 08:30

Sébastien Huron deviendra le président du directoire du groupe Virbac fin 2017 Carros, France - Le 23 juin 2017 Virbac annonce l'intention du conseil de surveillance de nommer Sébastien Huron président du directoire de [...]

Virbac : Sébastien Huron will become the new chairman of the executive board as of December 2017

23/06/2017 - 08:30

Virbac group: Sébastien Huron will become the new chairman of the executive board as of December 2017 Carros, France - June 23, 2017 Virbac has announced the supervisory board's intention to appoint Sébastien Huron as [...]

GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH

23/06/2017 - 08:30

GENFIT franchit une étape décisive pour le développement d'un test de diagnostic in-vitro (IVD) non-invasif dans la NASH Achèvement de la phase de faisabilité du programme de biomarqueurs dans la NASH après confirmation [...]

GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH

23/06/2017 - 08:30

GENFIT Reaches a Critical Milestone towards the Development of a Non-Invasive In Vitro Diagnostic (IVD) Test for NASH Completion of the NASH biomarker program feasibility phase, after confirmation of the competitive [...]

DiaSorin and Tecan to collaborate in new platform development

23/06/2017 - 07:25

Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 - DiaSorin (FTSE Italy Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN) announced today that they have agreed to collaborate in a development under which [...]

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

23/06/2017 - 07:00

PRESS RELEASE TiGenix to present at the 7 th TERMIS-EU Conference in Davos, Switzerland Leuven (BELGIUM) - June 23, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical [...]

Présentation de TiGenix à l'occasion de la 7ème Conférence TERMIS-UE à Davos (Suisse)

23/06/2017 - 07:00

COMMUNIQUÉ DE PRESSE Présentation de TiGenix à l'occasion de la 7 ème Conférence TERMIS-UE à Davos (Suisse) Louvain (BELGIQUE) - vendredi 23 juin 2017, 07h. CEST - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société [...]

Addex Shareholders Approved all Board Proposals at 2017 Annual General Meeting

23/06/2017 - 07:00

Roger Mills elected to the Addex Board of Directors Geneva, Switzerland, 23 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its shareholders approved all the proposals of the board of directors at its [...]

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

22/06/2017 - 23:42

Approval provides first targeted treatment in the US specifically for BRAF V600E mutation-positive metastatic NSCLC More than 60% of treatment-naïve and previously treated patients with BRAF V600E mutant metastatic [...]

Targovax ASA: Mandatory notification of trade by primary insider in relation to exercise of employee options

22/06/2017 - 22:15

1. Exercise of employee share options Berit Iversen, VP CMC of Targovax (the "Primary Insider"), has on 22 June 2017 subscribed for 25,000 shares in Targovax ASA at a price of NOK 7.5 per share in connection with her [...]

Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial

22/06/2017 - 20:19

PR170622_LEADER_EU_CHMP_Saxenda_UK This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mai 2017

22/06/2017 - 18:26

Communiqué de presse Villepinte, le 22 juin 2017 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]

AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH)

22/06/2017 - 17:41

Paris, 22 juin, 17h45 AB Science présente de nouvelles données positives de son étude de phase 3 dans la mastocytose systémique sévère au 22ème Congrès international de de l'Association Européenne d'Hématologie (AEH) Le [...]

AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA)

22/06/2017 - 17:41

Paris, June 22, 2017, 5.45pm AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22 nd Congress of the European Hematology Association (EHA) Abstract Selected for [...]

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia

22/06/2017 - 14:30

New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for [...]

Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris

22/06/2017 - 14:00

Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced [...]